dupilumab
sanofi,regeneron
['sanofi', 'regeneron']
at #eadv2022, we re presenting late-breaking results from a second positive phase 3 trial in adults with #prurigonodularis a debilitating disease characterized by unrelenting itch. read the news: 
Official channel for Regeneron. We turn science into medicine for people with serious diseases. View our terms of engagement here https://t.co/EuFDUdQQ5E